Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.

Robert H.I. Andtbacka,Brendan D. Curti,Gregory A. Daniels,Sigrun Hallmeyer,Eric D. Whitman,Jose Lutzky,Lynn E. Spitler,Karl Zhou,Praveen K. Bommareddy,Mark Grose,Meihua Wang,Cai Wu,Howard L. Kaufman

Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.

2021

Robert H.I. Andtbacka
Brendan D. Curti
Gregory A. Daniels
Sigrun Hallmeyer
Eric D. Whitman
Jose Lutzky
Lynn E. Spitler
Karl Zhou
Praveen K. Bommareddy
Mark Grose
Meihua Wang
Cai Wu
Howard L. Kaufman

PURPOSEWe evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma.PATIENTS AND METHODSIn this multicenter, open-label, phase II s...

Keywords:

in patient
Oncolytic virus
Oncology
Melanoma
Coxsackievirus A21
Stage IIIC
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations